Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 1
1994 1
1996 2
1997 2
1999 1
2004 1
2007 1
2010 2
2012 1
2013 1
2014 4
2015 4
2016 4
2017 3
2018 3
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Mapping a route to Indigenous engagement in cancer genomic research.
Henare KL, Parker KE, Wihongi H, Blenkiron C, Jansen R, Reid P, Findlay MP, Lawrence B, Hudson M, Print CG. Henare KL, et al. Among authors: findlay mp. Lancet Oncol. 2019 Jun;20(6):e327-e335. doi: 10.1016/S1470-2045(19)30307-9. Lancet Oncol. 2019. PMID: 31162106 Review.
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma.
Dasyam N, Sharples KJ, Barrow C, Huang Y, Bauer E, Mester B, Wood CE, Authier-Hall A, Dzhelali M, Ostapowicz T, Kumar R, Lowe J, Maxwell A, Burn OK, Williams GM, Carley SE, Caygill G, Jones J, Chan STS, Hinder VA, Macapagal J, McCusker M, Weinkove R, Brimble MA, Painter GF, Findlay MP, Dunbar PR, Gasser O, Hermans IF. Dasyam N, et al. Among authors: findlay mp. Cancer Immunol Immunother. 2023 Jul;72(7):2267-2282. doi: 10.1007/s00262-023-03400-y. Epub 2023 Mar 7. Cancer Immunol Immunother. 2023. PMID: 36881133 Free PMC article. Clinical Trial.
High CYP2C19 phenotypic variability in gastrointestinal cancer patients.
Burns KE, Lo WY, Findlay MP, Sharples K, Laking G, Helsby NA. Burns KE, et al. Among authors: findlay mp. Cancer Chemother Pharmacol. 2016 Jan;77(1):195-204. doi: 10.1007/s00280-015-2923-4. Epub 2015 Nov 27. Cancer Chemother Pharmacol. 2016. PMID: 26614509
The New Zealand PIPER Project: colorectal cancer survival according to rurality, ethnicity and socioeconomic deprivation-results from a retrospective cohort study.
Sharples KJ, Firth MJ, Hinder VA, Hill AG, Jeffery M, Sarfati D, Brown C, Atmore C, Lawrenson RA, Reid PM, Derrett SL, Macapagal J, Keating JP, Secker AH, De Groot C, Jackson CG, Findlay MP. Sharples KJ, et al. Among authors: findlay mp. N Z Med J. 2018 Jun 8;131(1476):24-39. N Z Med J. 2018. PMID: 29879724
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.
Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J. Hill AG, et al. Among authors: findlay mp. Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5. Clin Cancer Res. 2018. PMID: 29506988 Clinical Trial.
31 results